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Epidermodysplasia verruciformis (EV) is a rare disease, characterized by cutaneous warts and associated with a
strong predisposition to b-genus human papillomavirus (HPV). Earlier studies reported high copy numbers of
HPV-DNA in nearly all skin tumors from EV patients, but neither HPV replication status in non-lesional skin nor
anti-HPV seroreactivity in these patients have been reported yet. We therefore performed a comprehensive viral
load analysis for the more common b-HPV types on skin samples and plucked eyebrow hairs from four EV
patients treated at our dermatology department. The results clearly demonstrate that they carry a multiplicity
(up to eighteen types) of b-HPV genotypes in both skin sites. Worthy of note, a high intrapatient concordance
for specific types between hair bulbs and skin biopsies was observed and the same b-PV profile was maintained
over time. Viral load analysis revealed a load range between less than one HPV-DNA copy per 100 cells to more
than 400 HPV-DNA copies per cell in both eyebrow hairs and skin proliferative lesions. Evaluation of
seroreactivity to b-HPV types in the four EV patients revealed that antibodies against the 16 b-HPV were
significantly more prevalent and showed higher titers than in the controls.
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INTRODUCTION
Epidermodysplasia verruciformis (EV) is a rare genoderma-
tosis characterized by development of disseminated flat warts
since early childhood (Jablonska and Majewski, 1994). EV
patients are highly susceptible to human papillomavirus
(HPV) infection, and often develop cutaneous squamous-cell
carcinoma (SCC; Orth, 2006).
According to the most updated Papillomaviridae classifi-
cation, the HPV genotypes originally found in EV patients (for
example, EV-HPV) and phylogenetically related types are
grouped together into the Betapapillomavirus genus, whereas
the mucosal genotypes (for example, HPV types 16 and 18)
belong to the Alphapapillomavirus genus (deVilliers et al.,
2004).
The HPV types found more frequently in EV skin lesions
are 5, 8, 9, 12, 14, 15, 17, and 19–25. HPV types 5 and 8
have been detected in 90% of cutaneous SCC in EV cases,
and in two patients, HPV type 5 was detected in the primary
tumor and metastasis, suggesting a prominent role for HPV
type 5 in SCC (Orth, 1986; Favre et al., 1998; Majewski and
Jablonska, 2002; Pfister, 2003). HPV usually persists extra-
chromosomally in high copy numbers (100–300 per diploid
host genome) in nearly all SCCs from EV patients and is
actively transcribed. According to early in situ hybridization
(ISH) experiments, high copy numbers can be partially traced
back to a few carcinoma cells in the tumor, supporting
vegetative viral DNA replication (Orth et al., 1971, 1979;
Orth, 1980, 1986).
Highly sensitive detection techniques identified genus b-
papillomavirus (b-PV) DNA in a substantial proportion
(30–50%) of non-melanoma skin cancer in immunocompe-
tent non-EV patients (Boxman et al., 1997; Harwood and
Proby, 2002; Purdie et al., 2005; Akgul et al., 2006; Nindl
et al., 2007). The viral load in these skin tumors is low, with a
single HPV copy being detected in only 10–1,000 dysplastic
cells. The viral load may even decrease during skin
carcinogenesis (Weissenborn et al., 2005). These results are
in clear contrast with those obtained with mucosal HPV,
where HPV-induced genital cancers usually carry at least one
viral genome per cell, and where high viral load represents an
important risk factor for the development of cervical
carcinoma (Snijders et al., 2006). Moreover, b-PV DNA is
frequently detected in skin swabs and biopsies from normal
skin or in plucked hair bulbs from individuals with or without
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skin cancer, with a higher prevalence in sun-exposed sites
such as the forehead (Antonsson et al., 2000; Struijk et al.,
2003; de Koning et al., 2005; Kohler et al., 2007).
The majority of the HPV DNA detection studies performed
to localize and estimate the amount of virus present in EV
SCC date back to more than thirty years ago (Orth et al.,
1971, 1979; Orth, 1980, 1986). Over the last two decades,
several PCR-based methods have been developed to detect
and quantify a broad range of in part more recently identified
cutaneous HPV, and the sensitivity of the ISH technique has
been optimized as well. Furthermore, there is increasing
evidence that detection of EV-HPV DNA in eyebrow hairs
may be an adequate marker for the HPV type present in skin
lesions (Boxman et al., 1997, 2000; Struijk et al., 2003; Wolf
et al., 2004; Cronin et al., 2008). To further investigate the
replication status of these viruses in both lesional and non-
lesional skin from EV patients, we performed a comprehen-
sive viral load analysis for the more common b-genus HPV
types on skin samples and plucked eyebrow hairs from four
EV patients. We used quantitative real-time PCR (Q-PCR) and
ISH to determine the quantity and distribution of HPV in skin
biopsies and plucked eyebrows. In addition, serologic
analysis was performed to detect antibodies against the a,
b, g, m, and n genera of HPV in EV patients’ sera.
RESULTS
The clinical, virologic, genetic, and immunologic character-
izations of patients 1 and 2 have already been described
(Azzimonti et al., 2005; Zavattaro et al., 2008). The
histopathological features of patient 3 and 4—skin biopsies
(Figure 1B panels a and g)—together with the clinical history
were consistent with a diagnosis of EV. In addition, HPV
DNA analysis from both skin biopsies and plucked eyebrows
of patients 3 and 4 revealed the presence of multiple HPV
genotypes from the b-genus, as expected for EV patients.
Overall, analysis of eyebrow hair bulbs revealed multiple
b-genus HPV infections, with between 5 and 18 types of the
virus present (Table 1). HPV DNA analysis was performed by
using a newly developed broad spectrum PCR (PM-PCR) in
combination with a reverse hybridization system; de Koning
et al., 2006). To avoid discrepancy due to the PCR technique,
specimens from patient 1 and 2 that were previously
analyzed by CP(62/69)-based PCR were retested by the PM-
PCR. As PM-PCR is more sensitive than the CP(62/69)-PCR,
additional b-genus HPV types were identified (Table 1). All
previously detected types were confirmed here with PM-PCR.
The b-globin gene could no longer be amplified from the
DNA of the SCC specimen from patient 1, likely due to DNA
degradation. For this sample, ISH analysis was done with
HPV type 20, which was previously identified in this lesion
(Azzimonti et al., 2005). Interestingly, the highest number of
genotypes was found in hair bulbs from both forearm and
eyebrows, confirming the hypothesis that this site can
function as a reservoir of b-genus HPV types. By contrast,
PCR reactions for g-genotypes gave negative results in all the
specimens from the four study patients.
Next, to determine HPV DNA copy numbers and input
cell equivalents, type-specific Q-PCR protocols for HPV types
5, 8, 14, 15, 19, 20, 23, 24, 36, 38, 93, and 96 were
performed. Overall, HPV DNA loads in EV biopsies ranged
between less than 1 HPV DNA copy per less than 100 cells to
more than 400 HPV-DNA copies per cell. For patient 1, DNA
from three biopsies was available for Q-PCR; HPV type 36
predominated in both the actinic keratosis and the Bowenoid
lesion, whereas no HPV-type with a high viral load could be
observed for the wart-like lesion. For the papular lesion of
patient 2, no predominant type could be identified. For
patient 3, high loads could be seen for the wart-like lesion
(HPV types 8 and 24), the SCC (HPV types 24, 14, and 19),
and the Bowenoid lesion (HPV types 14 and 19). In patient 4,
HPV type 5 predominated in terms of viral loads in all four
skin biopsies. In the Bowenoid lesion, there were also high
load for both HPV types 93 and 96.
Consistent with the results obtained with skin biopsies,
HPV-DNA loads in hair bulbs from plucked eyebrows and
forearm hairs ranged between less than 1 HPV-DNA copy per
100 cells to more than 400 HPV-DNA copies per cell. In five
of the six hair bulb samples multiple HPV-types were seen at
high loads. Notably, the viral load of HPV type 5 was the
highest among the HPV genotypes quantified in plucked hair
bulbs from both eyebrows and forearm hairs from all four
patients, suggesting that a predominant replication of this
genotype is somehow favored in EV patients.
To localize viral HPV DNA in the context of the surgical
lesions, histological slides were prepared to perform ISH. The
choice of the probes was made on the basis of the Q-PCR
results. As a negative control, samples were hybridized with
the empty parental vector probe (data not shown) and an
unrelated genotype (HPV type 16). For patient 1, a very strong
signal was detected in the SCC lesion with the HPV type 20
probe and in the Bowenoid lesion with the HPV type 36
probe (Figure 1A panels a and c, respectively). Positive nuclei
were distributed heterogeneously in the tumor tissues. In the
papular lesion from patient 2, a weaker signal was obtained
with the HPV type 24 probe (Figure 1A panel e). Serial
sections from the skin biopsies of patient 3 showed a strong
signal in the Bowenoid lesion with HPV type 14 (Figure 1B
panel b) and 19 (data not shown), and in the wart-like lesion
with both HPV types 8 and 24 probes (Figure 1B panels d,
and e). In these lesions, HPV genomes were mainly detected
in the nuclei of the upper superficial layers. In the SCC
hybridized with HPV types 24, 14, and 19, the positive nuclei
were mostly located in the normal epithelium adjacent to the
tumor nests, where only scattered nuclei were positive (data
not shown). In both actinic keratosis and Bowenoid lesion
from patient 4, a strong signal was obtained with HPV type 5
(Figure 1B panel h and l), 93, and 96 (data not shown),
whereas very few positive cells were detectable in both SCC
and basal cell carcinoma hybridized with the same DNA
probes (data not shown).
Sera from the four EV patients and 54 age- and sex-
matched control individuals were analyzed in parallel for
antibodies to 38 HPV types. The sera were also analyzed for
three other control antigens that have a high seroprevalence
(VP1 from human polyoma virus JC; CagA and OMP from
Helicobacter pylori). In EV patients, antibodies against the 16
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b-PV were significantly more prevalent (89% of all reactions
positive versus 10% in the controls, Po0.0001; Figure 2), and
EV patient sera showed higher titers than the controls
(Po0.0001; Figure 2). Also, antibodies to g-PV were more
prevalent in EV patients (42 versus 10%, Po0.0001) and
elevated in titer (Po0.0001; Figure 2). This was also true for
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Figure 1. Human papillomavirus (HPV)-DNA detection in formalin-fixed paraffin-embedded skin biopsies by in situ hybridization (ISH). HPV-DNA positive
nuclei appear red (AEC staining; scale bar¼ 250mm). HPV type-specific DNA probes were used. (A) Patient 1. SCC: DNA-probe HPV type 20 (a), and Ctrl* (b);
Bowenoid lesion: DNA-probe HPV type 36 (c), and Ctrl (d). Patient 2. Papular lesion: DNA-probe HPV type 24 (e), Ctrl (f). (B) Patient 3. Bowenoid lesion:
H&E**(a), DNA-probe HPV type 14 (b), and Ctrl (c); Wart-like lesion: DNA-probe HPV type 8 (d), HPV type 24 (e), and Ctrl (f). Patient 4. AK: H&E (g), DNA-
probe HPV type 5 (h), and Ctrl (i); Bowenoid lesion: DNA-probe HPV type 5 (l), and Ctrl (m). *Ctrl: tissue specimens hybridized with the unrelated genotype
HPV type 16; **H&E: Hematoxylin-eosin staining.
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Table 1. Detection of DNA of cutaneous b-PV
genotypes and assessment of viral load in biopsy
specimens and plucked hair bulbs from EV study
patients
Patient
Sex/Age
Histology
(location) HPV type Viral load
HPV
type
Copies/
cell
1 M/401 Wart-like lesion
(forearm) 2003
52, 14, 15,
20, 24, 36
5 o0.01
14 o0.01
15 o0.01
20 o0.01
24 o0.01
36 o0.01
SCC (left temporal
region) 2003
20 NA3 NA3
AK (elbow) 2003 5, 15, 20,
24, 36
5 o0.01
15 o0.01
20 o0.01
24 o0.01
36 38
Bowenoid lesion
(forehead) 2003
5, 15, 20,
24, 36
5 o0.01
15 o0.01
20 o0.01
24 o0.01
36 16
Plucked hair
bulbs (eyebrows)
2007
5, 9, 12, 15,
20, 21, 22,
24, 36
5 416.7
15 147
20 270
24 o0.01
36 100
2 F/60 Papular lesion
(forearm) 2005
5, 14, 15, 24 5 o0.01
14 o0.01
15 o0.01
24 o0.01
Plucked hair bulbs
(eyebrows) 2007
5, 9, 14,
15, 24
5 312
14 o0.01
15 o0.01
24 o0.01
3 M/39 SCC (right
temporal
region) 1999
14, 19, 24 14 148
19 143
24 88
Bowenoid lesion
(right temporal
region) 1999
14, 19, 24 14 33.3
Table 1. Continued
Patient
Sex/Age
Histology
(location) HPV type Viral load
HPV
type
Copies/
cell
19 46.1
24 0.1
Wart-like lesion
(forearm) 1999
8, 24, 37 8 472
24 132
Plucked hair
bulbs (eyebrows)
2007
5,8, 9, 12,
14, 19, 21,
23, 24, 25,
36, 37, 38,
47, 49, 75
5 14
8 0.25
14 o0.01
19 o0.01
23 o0.01
24 0.09
36 0.02
38 o0.01
Plucked hair
bulbs (forearm)
2007
5, 8, 9, 12, 14,
17, 19, 21, 23,
24, 25, 36, 37,
38, 47, 49,
75, 76
5 125
8 3.3
14 o0.01
19 0.25
23 0.02
24 1
36 0.23
38 0.02
4 M/601 BCC (medial
left eyelid)
2007
5, 8, 15, 20,
21, 23, 25,
93, 96
5 4.6
8 o0.01
15 0.09
20 0.02
23 o0.01
93 0.02
96 0.02
AK (right cheek
bone) 2007
5, 19, 20, 21,
24, 25, 47
5 445
19 o0.01
20 o0.01
24 o0.01
SCC (medial
left eyelid) 1993
5, 20, 21, 25,
93, 96
5 3.4
20 o0.01
93 o0.01
96 o0.01
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the cutaneous and mucosal a- and cutaneous m-, and n-PV.
However, median b-PV titers in EV patients were 13 (b-
species 3, 4, 5) to 34 (b-species 1) times higher than controls,
whereas median titers for g-PV and a-/m-/n-PV were only
increased seven- and fourfold, respectively. The three control
antigens did not differ significantly between the two groups
(Figure 2). In the individual patients, the antibody responses
against the b-PV types with high viral load (4one copy per
cell) did not appear to differ from the response against the
other b-PV types (Table S1).
DISCUSSION
For the first time to our knowledge, this study characterizes
HPV infection in EV patients with precise typing, quantitative
tests, in situ localization, and antibody analysis. Despite the
small number of patients due to the extremely low incidence
of the disease, this study offered the unique possibility of
thoroughly evaluating different virologic parameters in EV
patients in both lesional and non-lesional skin. The results
obtained clearly demonstrate that EV patients carry a multi-
plicity (up to 18 types) of b-PV genotypes in both eyebrow
and hair bulbs from different skin sites, confirming and
expanding previous findings done on skin scrapes from EV
lesions (Orth, 1986). The most likely explanation for this
broader spectrum of genotypes is that the techniques used in
the past were less sensitive or the number of HPV probes
available was certainly much smaller. The rate of infection in
EV patients is much higher than that reported for either the
immunocompetent or immunosuppressed non-EV population
(Boxman et al., 1997, 1999, 2000). De Koning et al., (2007),
by investigating 23 healthy individuals over time for the
presence of b-PV DNA in plucked hairs with the same test
applied here, found a multiplicity of HPV types restricted in
the range of one to 10 b-PV types present simultaneously,
with 10 types found in one individual only.
Viral load analysis for the more common b-genus HPV
types in skin samples and plucked hair bulbs revealed a viral
load range between one DNA copy per 100 cells to more
than 400 DNA copies per cell. These finding are comparable
to those reported earlier by Orth et al. (1971, 1979) and Orth,
(1980, 1986), but much higher than those observed in our
previous study of a series of both premalignant and malignant
lesions from immunocompetent individuals (Weissenborn
et al., 2005). Importantly, in eyebrow hair bulbs from all four
patients, very high HPV loads were observed for some
(for example, HPV types 5) but not all types. These high
loads exceeded median loads observed in hair bulbs of
Table 1. Continued
Patient
Sex/Age
Histology
(location) HPV type Viral load
HPV
type
Copies/
cell
Bowenoid
lesion (back) 1990
5, 93, 96 5 618
93 53
96 73
Plucked hair bulbs
(eyebrows) 2008
5, 8, 14, 20,
21, 25, 36,
93, 96
5 111
8 o0.01
14 4.4
20 0.54
36 o0.01
93 1.1
96 0.65
Plucked hair bulbs
(forearm) 2008
5, 8, 14, 20,
21, 24, 25, 36,
47, 93, 96
5 71.8
8 o0.01
14 4.6
20 5.3
24 o0.01
36 o0.01
93 o0.01
96 0.9
AK, actinic keratosis; BCC, basal cell carcinoma; HPV, human papillo-
mavirus; SCC, squamous-cell carcinoma.
1Consanguinity.
2Normal font numbers: HPV identified by PM-PCR only; Bold numbers:
HPV identified previously by CP(62/69)-PCR.
3NA: not available.
10,000
1,000
100
10
1
<0.0001     <0.0001   <0.0001   <0.0001   <0.0001   <0.0001 0.23P (Wilcoxon)
α,μ,ν β1 β2 β 3,4,5 all β γ other
M
FI
Vera
EV
Figure 2. HPV serum antibody reactivity in EV patients (n¼ 4) and controls
(n¼ 54). The box plots show the distribution of serum antibody reactivities
measured by HPV multiplex serology and expressed as median fluorescence
intensity (MFI, logarithmic scale). Sera from 4 EV patients (EV) and 54 age-
matched control individuals of a population-based nutrition survey (VERA)
were analyzed with major capsid proteins L1 from 38 HPV types grouped by
phylogeny, and three other control antigens (VP1 from human polyoma virus
JC; CagA and OMP from Helicobacter pylori) with high seroprevalence. The
group a, m, n includes HPV types 2, 3, 7, 10, 13, 16, 18, 27, 57, 77, 1, 41 and
63 group b1 types 5, 8, 20, 24, and 36, group b2 types 9, 15, 17, 23, 38, and
107, group b3, 4, 5 types 49, 75, 76, 92, and 96, and group g types 4, 48, 50,
60, 65, 88, 95, 101, and 103. Boxes include the 25th to 75th percentile of
measurements, and the line within shows the median. Whiskers below and
above describe the 10th and 90th percentile. Values outside these boundaries
are shown by circles. The dotted lines represent the arbitrarily chosen uniform
cut-off of 200 MFI to define seropositivity for all HPV antigens and 800 for the
control antigens.
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immunocompetent and immunosuppressed patients from a
multicenter study by four orders of magnitude. In these
groups, less than 5% of the patients had loads comparable to
those of EV-patients (SJ Weissenborn et al., unpublished).
Despite the broad spectrum of b-genotypes found in the four
patients, a high intrapatient concordance for specific types
between hair bulbs and skin biopsies was observed. Worthy
of note, the same b-PV signature was maintained over time,
consistent with previous findings indicating that an individual
becomes colonized with a particular profile of b-PV,
probably from early infancy, which tends to persist (de
Koning et al., 2007; Cronin et al., 2008). In patients 2, 3, and
4 the HPV type 5 load was dominant, and in patient 1,
although other genotypes with high viral load were also
present, HPV type 5 again displayed the highest load (416
copies per cell versus 270 for HPV type 20, 147 for HPV type
15, and 100 for HPV type 36).
It has been speculated that HPV replication, and
presumably enhanced, gene expression may stimulate
keratinocyte proliferation and contribute to carcinogenesis
in the early stages of non-melanoma skin cancer develop-
ment by inhibition of apoptosis in response to UV damage
and binding of a protein required for repair of single-strand
DNA breaks (Jackson and Storey, 2000; Iftner et al., 2002;
Weissenborn et al., 2005). In line with this hypothesis, the
increased risk for SCC development in EV patients might be
due to a larger number of HPV-positive cells or higher viral
copy numbers per cell associated with an increased
concentration of viral oncoproteins, thus facilitating the
accumulation of UV-induced mutations and oncogenic
transformation in a larger fraction of cells.
There is increasing evidence that the clinical course of EV
can be radically different. The benign form only presents with
flat, wart-like lesions over the body, whereas the malignant
form shows a higher rate of polymorphic skin lesions and
development of multiple cutaneous tumors (Cortes-Franco
et al., 1997; de Oliveira et al., 2003; Gul et al., 2007).
Accordingly, the clinical course of patient 2 versus patients 1,
3, and 4 was radically different because the latter had
already developed several malignant and premalignant
lesions early in life, whereas patient 2 had not even though
she was almost 60. A possible explanation for this difference
may be found in the lower multiplicity of genotypes reported
in patient 2.
To localize viral HPV DNA, ISH was performed. Nests of
cells with strong signals were scattered in the Bowenoid
lesions from all patients and the SCC from patient 1, but not
in patients 3 and 4. However, the absence of signals in other
cells does not exclude the presence of a few viral copies
escaping detection by this technique, which is estimated to
be able to detect less than 10 copies per cell as deduced from
ISH experiments in transgenic mouse tissues (Weissenborn
et al., 2005). On the other hand, these results indicate viral
loads higher than those given in Table 1, and point to viral
replication in ISH-positive cells. The presence of cell nests
with active replication in the normal epithelium surrounding
the tumor area might also explain the weak signal in the SCC
lesion from patient 3 with HPV type 24, 14, and 19. As
suggested by the high viral loads, more distant serial sections
might have resulted in a different staining pattern. For both
papular and wart-like lesions, HPV genomes were mainly
detected in the nuclei of the superficial layers of the lesions,
as expected for productive lesions.
Epidemiological studies in immunocompetent individuals
revealed that the presence of b-genus HPV DNA, evaluated
as the number of specific types in eyebrow hairs, was
significantly associated with a history of SCC, but none of the
HPV types found was predominantly associated with skin
cancer (Boxman et al., 1997; Struijk et al., 2003; Bouwes
Bavinck et al., 2008). By contrast, in EV patients a
predominant association of skin cancer with HPV type 5
was reported (Orth et al., 1971, 1979; Orth, 1980, 1986). In
our study, we found several b-genotypes in the skin cancers
of EV patients (for example, 14, 19, 20, 24, and the genotypes
HPV types 93 and 96) never or rarely reported before.
Despite the presence of high viral loads in hair bulbs from all
EV study patients, HPV type 5 was only detected in the skin
cancers from patient 4. We can only speculate about possible
reasons for not finding a predominant oncogenic role for HPV
type 5. It may be related to different degree of UVB exposure,
genetic background or simply the small cohort of patients.
Worthy of note, only patient 4 carried a nonsense mutation in
the EVER2 gene, together with a nonsynonymous single
nucleotide polymorphism in the same gene (rs7208422) that
was present in all four patients (Zavattaro et al., 2008; E.Z.
and M.G. unpublished observations).
Altogether, our results demonstrate that (1) in all four
patients HPV type 5 is the predominant genotype in
eyebrows; (2) b-PV carriage in both hair bulbs and skin
biopsies was highly concordant with a broad spectrum of
genotypes; and (3) patients infected with HPV types 5 or 8
may develop cancer not attributable to either of these HPV
types.
In addition, this is the first report describing antibody
response to a broad variety of HPV types in EV patients.
Favre et al. (1998) had already noted that in EV patients,
antibodies to HPV type 5, but not to HPV type 1 are elevated.
We show here that the four EV patients, in comparison to age-
and sex-matched control individuals, have significantly
elevated antibody reaction to almost all of the 16 b-PV and
to a lesser extent to the 9 g-PV. The enhanced, genus-
restricted antibody response is thought to reflect higher viral
load of b-PV in the patients and is in line with the multiple b-
PV detected by DNA analysis. For g-PV, the slightly elevated
antibody response is not matched by positive DNA findings,
which might be due to lower sensitivity of the g-PV PCR used
here, or to only localized g-PV infections in contrast to the
ubiquity of b-PV. It cannot be excluded that the strong
reactivity to b-PV might be accompanied by some cross-
reactivity to other HPV, however, among the control sera
significant single reactions with one HPV type only are
present whereas closely as well as distantly related HPV types
showed no reaction (see Table S1). The serological results
thus reiterate the restriction of the HPV replication control
defect to a specific genus in EV patients. The high antibody
response also suggests that the EV patients do not have a
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defect in mounting an effective antibody response even
though the virus is not cleared.
Although interpretation of the study results is limited by
the small number of EV patients, several aspects of the
virological data obtained in this study deserve to be
stressed: (1) eyebrows from EV patients contain more
HPV types than those from the normal population, and they
may define the b-PV profile of these patients; (2) a
predominantly high viral load of HPV type 5 in the eyebrows
can be detected as a representative marker of the disease; (3)
high viral loads are maintained in skin proliferative lesions;
and (4) HPV seroreactivity is strongly elevated to almost
all b-PV.
MATERIALS AND METHODS
Patients
Four unrelated Caucasian patients with EV were included in this
study. Patients 1 and 2 were previously reported (Azzimonti et al.,
2005; Zavattaro et al., 2008). The third EV patient was a 39-year-old
man. Diagnosis of EV was made when he was 31 based on the
histological examination of two crusty and erythematous lesions
resected from the forehead that were diagnosed as microinvasive
SCC and an intraepithelial Bowenoid-type neoplasia, respectively.
He was the only person with EV in his family, and he was not
the result of a consanguineous marriage. The fourth EV patient was a
60-year-old man attending the ‘‘San Gallicano’’ Dermatologic
Institute, IRCCS-Rome. He was the only person with EV in his
family, and he was the result of a consanguineous marriage. Since
the age of 42, he underwent resection of several lesions from the
forehead and back that were diagnosed as either premalignant or
malignant (see Table 1). Medical history of both patients 3 and 4
was significant because of the presence since childhood of
numerous flat and papular lesions resembling verruca plana on his
forearms, chest, neck, upper limbs, and forehead, and whitish
pityriasis versicolor-like lesions on his back. All four patients were
HIV negative.
Written informed consent was obtained from the patients, and
ethical approval for this study was granted by the ‘‘Maggiore
Hospital’’ Research Ethics Committee, Novara. The present study
was conducted according to the Declaration of Helsinki principles.
HPV DNA detection
For hair samples 8–10 hairs were plucked from eyebrows, 4–5 from
each side. Only hairs that contained hair follicles were collected,
snap frozen, and stored at 70 1C until analysis. DNA was isolated
from hairs using a QIAamp DNA Mini Kit and eluted in 70 ml AE
buffer (Qiagen, Hilden, Germany). DNA extraction from formalin-
fixed paraffin-embedded skin biopsies was performed by using the
QIAamp Tissue Kit (Qiagen), according to the manufacturer’s
instruction. All specimens were examined by b-globin PCR to
estimate the quantity of DNA and to control its quality. HPV DNA
analysis for the b-genus was performed by using a PM-PCR in
combination with a reverse hybridization system (Skin (b) HPV
assay; Diassay BV, Rijswijk, The Netherlands; de Koning et al., 2006)
following the manufacturer’s instructions. The test comprises the
PM-PCR, generating a biotinylated amplimer of 117 bp from the E1
region, and a reverse hybridization assay, able to simultaneously
identify 25 b-PV types. This test has an analytical sensitivity of
10–100 viral genomes. Negative controls (water or human placental
DNA) and positive controls (1000 copies HPV type 8 plasmid) were
included in each analysis.
In addition, the single round primer pair C4F-C4R was used to
detect genus g-PV (HPV 4, 48, 50, 60, and 65) as previously reported
(Harwood et al., 1999).
Quantitative Real-Time PCR
Type-specific Q-PCR protocols for HPV types 5, 8, 15, 20, 23, 24,
36, 38, 14, 19, 93, and 96 were performed on the LightCycler system
(Roche Diagnostics, Mannheim, Germany), as previously described
(Wieland et al., 2000; Weissenborn et al., 2003; primer and probe
sequences for HPV types 14, 19, 23, and 38 are available on request
from SW). Primer- and probe-sequences for the quantification of
HPV types 93 and 96 were taken from Vasiljevic´ et al. (2007) and
protocols were adapted to the LightCycler system. HPV DNA copy
numbers were determined by using standard curves, generated in the
same PCR run with HPV plasmid dilutions ranging from 5 to 106
copies per sample in a human placental DNA solution (4 ng ml1).
Analytical sensitivity was 5–50 HPV DNA copies per reaction when
duplicate testing was performed. To correct for PCR efficiency and
DNA integrity and to determine the number of input cell equivalents,
the single-copy gene b-globin was quantified using the ‘‘LightCycler
Control Kit DNA’’ (Roche Diagnostics; Weissenborn et al., 2003). In
each PCR run, 5ml of EV patient DNA and 2 ml of plasmid DNA were
employed, respectively.
In situ hybridization
ISH was performed on formalin-fixed and paraffin-embedded skin
biopsies, applying the mild ISH protocol described in Hopman et al.,
2005. Briefly, tissue sections were dewaxed and digested with
8mgml1 pepsin (Sigma Chemical Co., St Louis, MO) in 0.2 M HCl
for 10minutes at 37 1C. Complete digoxigenin-labeled (DIG-Nick
Translation Mix; Roche Diagnostics GmbH, Mannheim, Germany)
genomic HPV plasmid DNA was used as the probe (100 ngml1).
Probe and target DNA were denatured simultaneously for 6minutes
at 90 1C prior to hybridization. HPV probes were detected using the
tyramide signal amplification procedure, according to manufac-
turer’s instructions (PerkinElmer Life and Analytical Sciences Inc.,
Shelton, CT).
Measurement of HPV antibodies
Frozen serum samples were shipped on dry ice to Dr Pawlita’s
laboratory at the German Cancer Research Center (DKFZ) in
Heidelberg, Germany. Sera from 36 male and 18 female participants
(all aged within 5 years of the EV patients) of a German nutrition
study (Verzehr, Erna¨hrung, and Risikoanalyse VERA) were used as
controls (Anders et al., 1990). Cutaneous HPV antibodies were
measured from all samples in one batch. Sera were tested for
antibodies to the major capsid protein L1 of genus a-PV (HPV types
2, 3, 7, 10, 13, 16, 18, 27, 57, and 77), genus b-PV (HPV types 5, 8,
9, 15, 17, 20, 23, 24, 36, 38, 49, 75, 76, 92, 96, and 107), genus
g-PV (HPV types 4, 48, 50, 60, 65, 88, 95, 101 and 103), the genus
m-PV types 1 and 63 and the genus n-PV type 41.
The antibody detection method was based on glutathione
S-transferase (GST) capture as described in Sehr et al. (2001, 2002)
in combination with fluorescent bead technology (Luminex) as
recently described (Waterboer et al., 2005, 2006). Detailed
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monoclonal antibody analysis with mucosal HPV has shown that
GST-L1 proteins like HPV L1 virus-like particles display conforma-
tional type-specific as well as cross-reactive epitopes (Rizk et al.,
2008). Generation and performance of the cutaneous GST-L1 fusion
proteins in serological assays has been described in detail (Michael
et al., 2008). Briefly, full-length viral proteins that were fused with a
N-terminal GST domain were expressed in bacteria. Glutathione
cross-linked to casein was coupled to fluorescently labeled poly-
styrene beads, and GST fusion proteins were directly affinity purified
on the beads in a one-step procedure. Bead sets of different color
and carrying different antigens were mixed and incubated with
human sera. Antibody bound to the beads via the viral antigens was
stained by biotinylated anti-human-Ig and streptavidin-R-phycoery-
thrin. Beads were analyzed in a Luminex analyzer that identifies the
bead color—and thus the antigen carried by the bead—and
quantifies the antibody bound to viral antigen via the median R-
phycoerythrin fluorescence intensity (MFI) of at least 100 beads of
the same internal color.
Statistical analysis
Statistical analysis of differences in seroprevalence were performed
by w2-tests. The Fisher’s exact test was used when frequencies were
smaller than or equal to five. Comparisons of seroreactivity (MFI
values) were performed by the Wilcoxon rank sum test. All tests were
two-sided, and P-values below 0.05 were considered statistically
significant.
CONFLICT OF INTEREST
The authors state no conflict of interest.
ACKNOWLEDGMENTS
We thank M. Risio (IRCC, Turin) for providing tissue specimens from EV
patient 3, and Ola Forslund (Lund University-Sweden) for providing plasmid
clones for HPV types 93 and 96. This study was supported by ‘‘Bando Ricerca
Applicata (CIPE 2004)’’, and ‘‘Progetto Ricerca Sanitaria Finalizzata’’ 2006
and 2008 from Regione Piemonte. V.D.O. is a recipient of a PhD Fellowship
from ‘‘Fondazione Cassa di Risparmio di Vercelli’’ and was also supported in
part by Fondazione Cariplo. T.W was supported by the ‘‘Peter und Traudl
Engelhorn-Stiftung zur Fo¨rderung der Biotechnologie und Gentechnik’’, and
S.W. by the ‘‘Deutsche Krebshilfe’’.
SUPPLEMENTARY MATERIAL
Table S1. Serum antibody reactivity in EV patients (n¼ 4) and controls
(n¼54) to 38 HPV types and 3 control antigens.
REFERENCES
Anders H, Rosenbauer J, Matiaske B (1990) Repra¨sentative Verzehrstudie in
der Bundesrepublik Deutschland incl. Schriftenreihe der Arbeitsge-
meinschaft Erna¨hrungsverhalten: Umschau Verlag
Akgul B, Cooke JC, Storey A (2006) HPV-associated skin disease. J Pathol
208:165–75
Antonsson A, Forslund O, Ekberg H, Sterner G, Hansson BG (2000) The
ubiquity and impressive genomic diversity of human skin papilloma-
viruses suggest a commensalic nature of these viruses. J Virol
74:11636–41
Azzimonti B, Mondini M, De Andrea M, Gioia D, Dianzani U, Mesturini R.
West-Berlinet al. (2005) CD8+ T-cell lymphocytopenia and lack of EVER
mutations in a patient with clinically and virologically typical
epidermodysplasia verruciformis. Arch Dermatol 141:1323–5
Bouwes Bavinck JN, Plasmeijer EI, Feltkamp MC (2008) Beta-papillomavirus
infection and skin cancer. J Invest Dermatol 128:1409–17
Boxman IL, Berkhout RJ, Mulder LH, Wolkers MC, Bouwes Bavinck JN,
Vermeer BJ et al. (1997) Detection of human papillomavirus DNA in
plucked hairs from renal transplant recipients and healthy volunteers.
J Invest Dermatol 108:712–5
Boxman IL, Hogewoning A, Mulder LH, Bouwes Bavinck JN, ter Schegget J
(1999) Detection of human papillomavirus types 6 and 11 in pubic
and perianal hair from patients with genital warts. J Clin Microbiol
37:2270–3
Boxman IL, Russell A, Mulder LH, Bavinck JN, Schegget JT, Green A (2000)
Case-control study in a subtropical Australian population to assess the
relation between non-melanoma skin cancer and epidermodysplasia
verruciformis human papillomavirus DNA in plucked eyebrow hairs. Int
J Cancer 86:118–21
Cortes-Franco R, Tyring SK, Vega E, Payne D, Granados J, Domiguez-Soto L
et al. (1997) Divergent clinical course of epidermodysplasia verruci-
formis in siblings. Int J Dermatol 36:442–5
Cronin JG, Mesher D, Purdie K, Evans H, Breuer J, Harwood CA et al. (2008)
b-Papillomavirus and psoriasis: an intra-patient comparison of
human papillomavirus carriage in skin and hair. Br J Dermatol
159:113–9
de Koning M, Struijk L, Feltkamp M, ter Schegget J (2005) HPV DNA detection
and typing in inapparent cutaneous infections and premalignant lesions.
Methods Mol Med 119:115–27
de Koning M, Quint W, Struijk L, Kleter B, Wanningen P, van Doorn MJ et al.
(2006) Evaluation of a novel highly sensitive, broad-spectrum PCR-
reverse hybridization assay for detection and identification of beta-
papillomavirus DNA. J Clin Microbiol 44:1792–800
de Koning MN, Struijk L, Bavinck JN, Kleter B, ter Schegget J, Quint WG et al.
(2007) Betapapillomaviruses frequently persist in the skin of healthy
individuals. J Gen Virol 88(Pt 5):1489–95
de Oliveira WR, Festa Neto C, Rady PL, Tyring SK (2003) Clinical aspects of
epidermodysplasia verruciformis. J Eur Acad Dermatol Venereol
17:394–8
de Villiers EM, Fruquet C, Broken TR, Bernard UR, zur Hausen H (2004)
Classification of papillomavirus. Virology 324:17–27
Favre M, Orth G, Majewski S, Baloul S, Pura A, Jablonska S et al. (1998)
Psoriasis: A possible reservoir for human papillomavirus type 5, the virus
associated with skin carcinomas of epidermodysplasia verruciformis.
J Invest Dermatol 110:311–7
Gul U, Kilic A, Gonul M, Cakmak SK, Bayis SS (2007) Clinical aspects of
epidermodysplasia verruciformis and review of the literature. Int J
Dermatol 46:1069–72
Harwood CA, Proby CM (2002) Human papillomaviruses and non-melanoma
skin cancer. Curr Opin Infect Dis 15:101–14
Harwood CA, Spink PJ, Surentheran T, Leigh IM, de Villiers EM, McGregor JM
et al. (1999) Degenerate and nested PCR: a highly sensitive and specific
method for detection of human papillomavirus infection in cutaneous
warts. J Clin Microbiol 37:3545–55
Hopman AH, Kamps MA, Smedts F, Speel EJ, Herrington CS, Ramaekers FC
(2005) HPV in situ hybridization: impact of different protocols on the
detection of integrated HPV. Int J Cancer 115:419–28
Iftner T, Elbel M, Schopp B, Hiller T, Loizou JI, Caldecott KW et al. (2002)
Interference of papillomavirus E6 protein with single-strand break repair
by interaction with XRCC1. EMBO J 21:4741–8
Jablonska S, Majewski S (1994) Epidermodysplasia verruciformis:
immunological and clinical aspects. Curr Top Microbiol Immunol
186:157–75
Jackson S, Storey A (2000) E6 proteins from diverse cutaneous HPV
types inhibit apoptosis in response to UV damage. Oncogene 19:
592–8
Kohler A, Forschner T, Meyer T, Ulrich C, Gottschling M, Stockfleth E
et al. (2007) Multifocal distribution of cutaneous human papillo-
mavirus types in hairs from different skin areas. Br J Dermatol 156:
1078–80
Majewski S, Jablonska S (2002) Do epidermodysplasia verruciformis human
papillomaviruses contribute to malignant and benign epidermal pro-
liferations? Arch Dermatol 138:649–54
www.jidonline.org 1033
V Dell’Oste et al.
Viral Load and Serum Reactivity in EV
Michael KM, Waterboer T, Sehr P, Rother A, Reidel U, Boeing H et al. (2008)
Seroprevalence of 34 human papillomavirus types in the German
general population. PLoS Pathog 4:e1000091
Nindl I, Gottschling M, Stockfleth E (2007) Human papillomaviruses and non-
melanoma skin cancer: basic virology and clinical manifestations. Dis
Markers 23:247–59
Orth G (1980) Epidermodysplasia verruciformis: a model for understanding
the role of Papillomavirus in Human Cancer. In: Viruses in Naturally
occurring cancers Book A. (Essex M, Todaro G, zur Hausen H eds) Cold
Spring Harbor Laboratory: Woodbury NY, 259–81
Orth G (1986) Epidermodysplasia verruciformis: a model for understanding the
oncogenicity of human papillomaviruses. Ciba Found Symp 120:157–74
Orth G (2006) Genetics of epidermodysplasia verruciformis: Insights into host
defense against papillomaviruses. Semin Immunol 18:362–74
Orth G, Jablonska S, Jarzabek-Chorzelska M, Obalek S, Rzesa G, Favre M
et al. (1979) Characteristics of the lesions and risk of malignant
conversion associated with the type of human papillomavirus involved
in epidermodysplasia verruciformis. Cancer Res 39:1074–1082
Orth G, Jeanteur P, Croissant O (1971) Evidence for and localization of
vegetative viral DNA replication by autoradiographic detection of RNA-
DNA hybrids in sections of tumors induced by Shope papilloma virus.
Proc Natl Acad Sci USA 68:1876–80
Pfister H (2003) Chapter 8: Human papillomavirus and skin cancer. J Natl
Cancer Inst Monogr 31:52–6
Purdie KJ, Surentheran T, Sterling JC, Bell L, McGregor JM, Proby CM et al.
(2005) Human papillomavirus gene expression in cutaneous squamous
cell carcinomas from immunosuppressed and immunocompetent
individuals. J Invest Dermatol 125:98–107
Rizk RZ, Christensen ND, Michael KM, Mu¨ller M, Sehr P, Waterboer T et al.
(2008) Reactivity pattern of 92 monoclonal antibodies with 15 human
papillomavirus types. J Gen Virol 89(Pt 1):117–29
Sehr P, Muller M, Hopfl R, Widschwendter A, Pawlita M (2002) HPV
antibody detection by ELISA with capsid protein L1 fused to glutathione
S-transferase. J Virol Methods 106:61–70
Sehr P, Zumbach K, Pawlita M (2001) A generic capture ELISA for
recombinant proteins fused to glutathione S-transferase: validation for
HPV serology. J Immunol Methods 253:153–62
Snijders PJ, Hogewoning CJ, Hesselink AT, Berkhof J, Voorhorst FJ, Bleeker
MC et al. (2006) Determination of viral load thresholds in cervical
scrapings to rule out CIN 3 in HPV 16, 18, 31 and 33-positive women
with normal cytology. Int J Cancer 119:1102–7
Struijk L, Bouwes Bavinck JN, Wanningen P, van der Meijden E, Westendorp
RG, Ter Schegget J et al. (2003) Presence of human papillomavirus DNA
in plucked eyebrow hairs is associated with a history of cutaneous
squamous cell carcinoma. J Invest Dermatol 121:1531–5
Vasiljevic´ N, Hazard K, Eliasson L, Ly H, Hunziker A, de Villiers EM et al.
(2007) Characterization of two novel cutaneous human papilloma-
viruses, HPV93 and HPV96. J Gen Virol 88(Pt 5):1479–83
Waterboer T, Sehr P, Michael KM, Franceschi S, Nieland JD, Joos TO
et al. (2005) Multiplex human papillomavirus serology based on
in situ-purified glutathione s-transferase fusion proteins. Clin Chem
51:1845–53
Waterboer T, Sehr P, Pawlita M (2006) Suppression of non-specific binding in
serological Luminex assays. J Immunol Methods 309:200–4
Weissenborn SJ, Funke AM, Hellmich M, Mallmann P, Fuchs PG,
Pfister HJ et al. (2003) Oncogenic human papillomavirus DNA
loads in human immunodeficiency virus-positive women with high-
grade cervical lesions are strongly elevated. J Clin Microbiol 41:
2763–7
Weissenborn SJ, Nindl I, Purdie K, Harwood C, Proby C, Breuer J et al. (2005)
Human papillomavirus-DNA loads in actinic keratoses exceed those in
non-melanoma skin cancers. J Invest Dermatol 125:93–7
Wieland U, Jurk S, Weissenborn S, Krieg T, Pfister H, Ritzkowsky A et al.
(2000) Erythroplasia of queyrat: coinfection with cutaneous carcinogenic
human papillomavirus type 8 and genital papillomaviruses in a
carcinoma in situ. J Invest Dermatol 115:396–401
Wolf P, Seidl H, Back B, Binder B, Hofler G, Quehenberger F et al. (2004)
Increased prevalence of human papillomavirus in hairs plucked from
patients with psoriasis treated with psoralen-UV-A. Arch Dermatol
140:317–24
Zavattaro E, Azzimonti B, Mondini M, De Andrea M, Borgogna C, Dell’Oste
V et al. (2008) Identification of defective Fas function and variation of the
perforin gene in an Epidermodysplasia Verruciformis patient lacking
EVER1 and EVER2 mutations. J Invest Dermatol 128:732–5
1034 Journal of Investigative Dermatology (2009), Volume 129
V Dell’Oste et al.
Viral Load and Serum Reactivity in EV
